Johnson & Johnson Offers $5.5 bn to Settle Talc‑Related Cancer Lawsuits

Mon Sep 14 2026 11:59:59 GMT+0000 (Coordinated Universal Time)

J&J proposes a $5.5bn settlement to resolve 69,000 ovarian‑cancer claims linked to its talc products, aiming to finally close the legal firestorm.

Johnson & Johnson announced a proposal to pay up to $5.5 bn (£4.14 bn) to settle tens of thousands of lawsuits alleging its talc‑based baby powder triggered ovarian cancer. The settlement would cover roughly 69,000 cases, with the bulk of payments due by 2028 and an initial $3 bn payout next year. Company officials, including VP of litigation Erik Haas, have dismissed the allegations as meritless, stressing the brand’s safety record. The offer seeks approval from lawyers representing 95% of the claims before it can be finalized. With this move, J&J hopes to put the long‑running litigation behind it and refocus on product development.

Johnson & Johnson Offers $5.5 bn to Settle Talc‑Related Cancer Lawsuits

Johnson & Johnson (J&J) has offered to pay as much as $5.5 bn (£4.14 bn) to resolve tens of thousands of lawsuits in the United States that claim the company’s baby powder and other talc‑containing products caused ovarian cancer.

The proposal would close a long running legal battle that has weighed on the New Jersey‑based healthcare giant for years. The settlement would cover about 69,000 cases, most of the remaining talc‑related claims. J&J will offer up to $3 bn next year, with no additional payments due before 2028.

Erik Haas, the company’s vice president of litigation, said on Monday that the allegations are “meritless” and that J&J is willing to settle in order to finally resolve the matter. He added that the company is confident it would have ultimately prevailed with further litigation, as it has in the majority of cases heard in court to date.

The proposal must be accepted by legal firms representing 95% of the ovarian cancer claims in state and federal courts before it can be finalized. J&J’s former consumer health business, Kenvue, holds liability for Johnson’s baby powder outside North America. Kenvue was spun off from J&J in 2022 and owns well‑known brands such as Band‑Aid, Listerine and Calpol.

Lawsuits against J&J over its talc‑based baby powder date back to 2009. Earlier in July, a federal court questioned individuals’ ability to show that talc was the direct cause of their ovarian cancer. Talc is a naturally occurring mineral used for its soapy feel; it is often mined in seams close to asbestos, a known carcinogen. J&J denies that its talc products are contaminated with asbestos and claims studies show it is safe.

In 2022, J&J announced it would stop making and selling its talc‑based baby powder worldwide, transitioning to an all cornstarch‑based portfolio. The decision came more than two years after it had ended sales of the product in the US.